+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 5 Actively Recruiting clinical trials

B

Actively Recruiting

Healthy Volunteer

Researchers are collecting blood and tissue samples from people with and without cancer to help develop and evaluate tests for early cancer detection. This observational study aims to create a blinded reference set of blood samples from cancer and non-cancer patients to validate new blood-based multi-cancer early detection tests. The study also evaluates test performance at the time of initial cancer diagnosis by tumor type and clinical stage. Participants complete a questionnaire at the start of the study and provide blood samples at registration and again 12 months later. Patients diagnosed with cancer may also provide tissue samples at these same times. The study collects these biospecimens to help researchers study and validate early cancer detection assays in the laboratory. During the study, participants are monitored with follow-up at one year after enrollment. Researchers assess the quality and usefulness of the collected blood samples as a blinded reference set for cancer detection tests. The main outcome is the provision of these samples over up to one year, with additional evaluation of test performance by tumor type and stage. Participants involvement includes questionnaires, blood draws, and possible tissue sample collection, with no treatment interventions involved.

Age: 40Years - 75YearsAll Genders
751 locations
C

Actively Recruiting

Researchers are evaluating two treatment approaches for diabetic foot ulcers DFUs to determine if adding Omeza Complete Matrix OCM to the standard of care SOC improves the chances of complete wound healing. This open-label study involves adult participants diagnosed with Type I or II diabetes who have DFUs that have not healed significantly with SOC alone. The trial includes a randomized design with a crossover option for participants whose wounds do not fully close after initial treatment. Participants will be randomly assigned to receive either SOC alone or SOC combined with OCM. SOC includes surgical sharp debridement, offloading using a total contact cast TCC or fixed ankle-walker, and proper moisture balance. Those in the SOC group who do not achieve complete wound closure by about 84 days post-randomization may cross over to receive OCM applications weekly for up to 12 visits. The study is conducted across multiple medical centers and gathers data on treatment efficacy while aiding insurance reimbursement decisions. During the study, participants will attend regular visits to receive their assigned treatments and undergo wound assessments, including measuring wound area changes and pain levels. Researchers will monitor complete wound closure within 1 to 12 weeks as the primary outcome. Secondary outcomes include changes in wound size and pain assessment. The total study duration extends up to March 2027, with ongoing follow-up after treatment. Participants must meet specific health and wound criteria and follow protocol requirements throughout the trial.

Age: 18Years +All GendersPhase Not Applicable
10 locations
S

Actively Recruiting

Researchers are developing a test to detect gynecologic cancersspecifically endometrial, ovarian, and cervical cancersusing cancer-specific methylated DNA markers MDMs and high-risk human papilloma virus HR-HPV found in vaginal fluid and plasma. This Phase II study aims to improve early cancer detection, which can significantly increase the chance of cure and reduce the need for invasive procedures. The study also explores new markers for cervical cancer and tests the specificity of these markers against common benign gynecologic conditions. Participants are grouped based on their symptoms or diagnoses, including women with abnormal uterine or postmenopausal bleeding, biopsy-proven endometrial or ovarian cancer, cervical pathology, benign gynecologic conditions, or healthy controls. Samples of vaginal fluid and blood will be collected before any exams or procedures. The study involves multiple cohorts representing different gynecologic conditions and healthy women to validate the MDM panels and their ability to distinguish cancer from benign conditions. During the study, participants will provide vaginal fluid and blood samples, and clinical data will be collected. Researchers will use these samples to develop and validate predictive models that identify endometrial and ovarian cancers. They will also assess false positive rates in women undergoing surgery for benign gynecologic diseases. The study monitors outcomes over 18 months to evaluate the accuracy of these tests and improve early detection methods for gynecologic cancers.

Age: 18Years +FEMALE
25 locations
M

Actively Recruiting

Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.

Age: 18Years +All Genders
2393 locations
O

Actively Recruiting

Researchers are conducting a large, multi-country observational study called LIVER-R to collect real-world data on patients with hepatobiliary cancers, including unresectable hepatocellular carcinoma uHCC, advanced biliary tract cancer aBTC, and other related liver cancers. The study aims to evaluate the effectiveness of treatment regimens that include durvalumab-based therapies or other approaches used in routine clinical practice or early access programs. The study is descriptive and will analyze survival as well as other important clinical outcomes over time. Participants will be observed during their regular clinical care, with data collected both prospectively during visits and retrospectively from medical records, covering a baseline period of up to 5 years before treatment initiation. The study groups include patients receiving durvalumab-based regimens alone or in combination with local regional therapy LRT, as well as those treated with non-durvalumab therapies. Follow-up will continue for at least 2 years or until death, loss to follow-up, withdrawal, or study end. Throughout the study, researchers will gather information on survival rates, treatment duration, progression, recurrence, liver function, treatment patterns, adverse events requiring medical intervention, and patient and provider characteristics. Data will be collected at enrollment and every six months, with real-world overall survival as the primary measure. This extensive monitoring aims to provide a comprehensive view of treatment outcomes and patient experiences in real-world settings across multiple hepatobiliary cancer types.

Age: 18Years - 130YearsAll Genders
161 locations